BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 35297009)

  • 21. Sprouty 1 predicts prognosis in human epithelial ovarian cancer.
    Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
    Am J Cancer Res; 2015; 5(4):1531-41. PubMed ID: 26101716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Refining breast cancer biomarker discovery and drug targeting through an advanced data-driven approach.
    Rakhshaninejad M; Fathian M; Shirkoohi R; Barzinpour F; Gandomi AH
    BMC Bioinformatics; 2024 Jan; 25(1):33. PubMed ID: 38253993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comprehensive atlas of epigenetic regulators reveals tissue-specific epigenetic regulation patterns.
    Wang J; Shi A; Lyu J
    Epigenetics; 2023 Dec; 18(1):2139067. PubMed ID: 36305095
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.
    Fountzilas G; Valavanis C; Kotoula V; Eleftheraki AG; Kalogeras KT; Tzaida O; Batistatou A; Kronenwett R; Wirtz RM; Bobos M; Timotheadou E; Soupos N; Pentheroudakis G; Gogas H; Vlachodimitropoulos D; Polychronidou G; Aravantinos G; Koutras A; Christodoulou C; Pectasides D; Arapantoni P
    J Transl Med; 2012 Jan; 10():10. PubMed ID: 22240029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.
    Arriola E; Rodriguez-Pinilla SM; Lambros MB; Jones RL; James M; Savage K; Smith IE; Dowsett M; Reis-Filho JS
    Breast Cancer Res Treat; 2007 Dec; 106(2):181-9. PubMed ID: 17260090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.
    Tubbs R; Barlow WE; Budd GT; Swain E; Porter P; Gown A; Yeh IT; Sledge G; Shapiro C; Ingle J; Haskell C; Albain KS; Livingston R; Hayes DF
    J Clin Oncol; 2009 Aug; 27(24):3881-6. PubMed ID: 19620488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer.
    An X; Xu F; Luo R; Zheng Q; Lu J; Yang Y; Qin T; Yuan Z; Shi Y; Jiang W; Wang S
    BMC Cancer; 2018 Mar; 18(1):331. PubMed ID: 29587760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
    Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
    Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer.
    Wu Y; Han Y; Li Q; Zhang P; Yuan P; Luo Y; Fan Y; Chen S; Cai R; Li Q; Xu H; Wang Y; Ma F; Wang J; Xu B
    Breast Cancer Res Treat; 2022 Jun; 193(2):381-392. PubMed ID: 35297009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.
    Romero A; Martín M; Cheang MC; López García-Asenjo JA; Oliva B; He X; de la Hoya M; García Sáenz JÁ; Arroyo Fernández M; Díaz Rubio E; Perou CM; Caldés Llopis T
    Am J Pathol; 2011 Apr; 178(4):1453-60. PubMed ID: 21435434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment.
    Bouchalova K; Cizkova M; Cwiertka K; Trojanec R; Hajduch M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):13-7. PubMed ID: 19365520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients.
    Petrelli F; Viale G; Cabiddu M; Barni S
    Breast Cancer Res Treat; 2015 Oct; 153(3):477-91. PubMed ID: 26341751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis.
    Ergun Y; Ucar G; Akagunduz B
    Cancer Treat Rev; 2023 Apr; 115():102538. PubMed ID: 36898351
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.